

## ***Supplementary Material***

### **1      Supplementary Data**

#### **1.1    ENFORCE Study Group Members**

A list of ENFORCE Study Group Members is available on the next page.

## **ENFORCE Study Group**

**Sponsor/Data and Statistical Centre:** CHIP, Rigshospitalet under the direction of Professor J Lundgren.

**Principal Investigator:** Professor LJ Østergaard, Department of Infectious Diseases, Aarhus University and Aarhus University Hospital.

**Sites** (alphabetical and regional coordinators in parenthesis)

**Region Hovedstaden:** (T Benfield), L Krohn-Dehli, DK Petersen, Hvidovre Hospital, Hvidovre. K Fogh, E Højmark, (K Iversen), Herlev Hospital, Herlev.

**Region Midtjylland:** V Klastrup, F Larsen, (NB Stærke), S Schieber, A Søndergaard, M Tousgaard, Y Yehdego, Aarhus University Hospital, Aarhus.

**Region Nordjylland:** J Bodilsen, (H Nielsen), KT Petersen, M Ruwald, RK Thisted, Aalborg University Hospital, Aalborg.

**Region Sjælland:** SF Caspersen, M Iversen, LS Knudsen, JL Meyerhoff, LG Sander, (L Wiese), Zealand University Hospital Roskilde, Roskilde.

**Region Syddanmark:** C Abildgaard, IK Holden, (IS Johansen), L Larsen, SO Lindvig, LW Madsen, A Øvrehus, Odense University Hospital, Odense.

**Scientific Steering Committee:** NA Kruse, H Lomholdt, Lægemiddelstyrelsen, TG Krause, P Valentiner-Branth, Statens Serum Institut, B Søborg, Sundhedsstyrelsen, TK Fischer, Copenhagen University, C Erikstrup, Aarhus University, SR Ostrowski, Rigshospitalet, H Nielsen, Aalborg University Hospital, IS Johansen, Odense University Hospital, LJ Østergaard (chair), M Tolstrup, NB Stærke, OS Søgaard Aarhus University Hospital, L Wiese, Zealand University Hospital Roskilde, T Benfield, Hvidovre Hospital, J Lundgren, D Raben, CHIP, Rigshospitalet.

**Operational Group:** H Nielsen, Aalborg University Hospital, IS Johansen, Odense University Hospital, LJ Østergaard, M Tolstrup, NB Stærke, OS Søgaard, Aarhus University Hospital, L Wiese, Zealand University Hospital Roskilde, T Benfield, Hvidovre Hospital, J Lundgren (chair), D Raben, CHIP, Rigshospitalet, E Jylling, Danske Regioner, D Hougaard, Statens Serum Institut.

**Coordinating Centre:** Aarhus University and Aarhus University Hospital, SD Andersen, K Lykkegaard, NB Stærke, OS Søgaard, M Tolstrup, LJ Østergaard.


**ENFORCE Lab:** Aarhus University Hospital: SR Andreasen, E Baerends, LL Dietz, AK Hvidt, AK Juhl, R Olesen, M Tolstrup.

**Data and Statistical Centre:** CHIP, Rigshospitalet: KK Andersen, W Bannister, C Bjernved, FV Esmann, E Gravholdt, CM Jensen, SF Jakobsen, ML Jakobsen, TØ Jensen, D Kristensen, J Lundgren, C Matthews, N Normand, C Olsson, D Raben, J Reekie, A Traytel.


**Other contributors:** AM Hvass, H Støvring, Aarhus University Hospital, Statens Serum Institut.

**Funding:** ENFORCE has received a grant from the Danish Ministry of Health (SUM) (legal deeds 150 28/1 2021 and 263 3/6 2021).

## 2 Supplementary Figures



**Supplementary Figure 1 - Spearman's Correlation for all SARS-CoV-2 Variants:**  
**(A)** Spearman's correlation between SARS-CoV-2-S NT50 values quantified by the pseudovirus neutralization assay and ACE2 receptor-blocking antibodies in U/ml and **(B)** ACE2 receptor blocking in percentage quantified by the MSD ACE2 competition assay (n = 110). From left to right: SARS-CoV-2-S B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.351 (Beta).



**Supplementary Figure 2 – Levels of SARS-CoV-2-S IgG after COVID-19 Booster Vaccination:**

Levels of total SARS-CoV-2-S IgG in U/mL after booster vaccination with BNT162b2 ( $n = 11$ ), mRNA-1273 ( $n = 12$ ), ChAdOx1 ( $n = 5$ ) and Ad26.COV2.S ( $n = 6$ ) quantified by the MSD platform (plasma 1:5,000). From left to right: SARS-CoV-2-S wt (Wuhan-Hu-1) and B.1.1.529; BA.1, BA.2 and BA.3 (Omicron). All boxplots present the lower quartile, median and upper quartile, and the error bars indicate 95% CI.